Industry Insights on Cell Line Development Timelines and Challenges
Summary
Explore a comprehensive analysis of cell line development (CLD) timelines from BioPhorum’s industry-wide survey. This extensive study provides valuable benchmarks on the time and effort required at each stage of CLD, including vector design, transfection, and single-cell cloning, as well as insights on challenges specific to antibody and complex molecule production. By surveying multiple companies across the biopharmaceutical field, this publication offers a robust overview of how various teams navigate the intricacies of developing high-yield CHO cell lines under evolving timelines.
Research highlights
- Study Title: When will we have a clone? An industry perspective on the typical CLD timeline
- Authors: Howard Clarke, Anke Mayer-Bartschmid, Chenxing Zheng, Elizabeth Masterjohn, Falguni Patel, Mark Moffat, Qingxiang Wei, Ren Liu, Robyn Emmins, Simon Fischer, Stephanie Rieder, Thomas Kelly
- Published In: Biotechnolopgy Progress, 2023
- DOI: 10.1002/btpr.3449
Key findings
- Detailed breakdown of CLD phases: vector design, transfection, cloning, and lead selection
- Industry comparison between antibody and complex molecule workflows
- Key insights on accelerating development timelines in response to market demands
The Next Generation: Cyto-Mine® Chroma
Automate. Accelerate. Analyze millions of cells in a single day.
Think Cyto-Mine®, but supercharged, enabling multiplexing and greater assay flexibility to fit your needs. It means that you can examine vastly greater numbers of cells — and isolate the most valuable ones— with unparalleled precision.
Cyto-Mine® Chroma
Contact sales
